


ISLHD HAEMATOLOGY CLINICAL TRIALS

April 2022

ISLHD CANCER CLINICAL TRIALS UNIT

Illawarra Cancer Care Centre
Wollongong Hospital
Loftus Street
Wollongong NSW 2500

Clinical Trials available through the Illawarra Shoalhaven Local Health District can be found on the Haematology NSW/ACT ClinTrial Refer App on iTunes and Google Play.



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong Hospital in the Illawarra Cancer Care Centre and Shoalhaven Hospital in the Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Lymphoma (Non-Hodgkins and Hodgkins)
- Myelodysplastic syndromes
- Myelofibrosis
- Multiple Myeloma
- Acute Leukaemia
- Chemotherapy induced nausea and vomiting

REFERRAL OR CONSULTATION

To discuss your patients treatment options with an ISLHD Haematology Trials Clinician, please call:


Haematology 02 4253 4009

Clinical Trials Unit

Phone: +61 2 4253 4384







Fax: +61 2 4222 5085

Email: ISLHD-CancerClinicalTrials@health.nsw.gov.au









ISLHD HAEMATOLOGY CLINICAL TRIALS CURRENTLY OPEN FOR RECRUITMENT

Use the hyperlink in study name or corresponding QR Code to find out more eligibility information

MALIGNANCY	TRIAL NAME	Investigator + Coordinator	QR code
Multiple Myeloma	<u>ACT16482:</u> Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM).	Dr Parmar Danielle di Pietro/ Molly Clarris/ Tiffany Koutsouradis	
	<u>CANOVA:</u> A phase 3, multicenter, randomized, open label study of venetoclax and dexamethasone compared with pomalidomide and dexamethasone in subjects with t(11;14)-positive relapsed or refractory multiple myeloma.	Dr Parmar Danielle di Pietro	
	<u>ITHACA:</u> A phase 3 randomized, open label, multicenter study of Isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma.	Dr Parmar Shantel Dale / Lisa Kelly / Madi Corry	
	<u>MMY1004:</u> A multi-arm phase 1b study of talquetamab with other anticancer therapies in participants with multiple myeloma.	Dr Parmar Danielle di Pietro / Molly Clarris	
Myelodysplastic syndromes	<u>COMMANDS:</u> A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk due to myelodysplastic syndrome (MDS) ESA in naïve subjects who require red blood cell transfusions.	Dr Presgrave Danielle di Pietro (ICCC) Kyrie Rodgers (SCCC)	
& AML	<u>CA059-001:</u> A phase 1, open-label, dose finding study of CC-95251 alone and in combination with antineoplastic agents in subjects with acute myeloid leukemia and myelodysplastic syndromes.	Dr Presgrave Patricia Blyton	

ISLHD HAEMATOLOGY CLINICAL TRIALS CURRENTLY OPEN FOR RECRUITMENT

Use the hyperlink in study name or corresponding QR Code to find out more eligibility information

Acute Leukaemia	<u>VIALE-M</u> : A randomized, double-blind, 2-arm, multicenter, phase 3 study of venetoclax and oral azacitidine versus oral azacitidine as maintenance therapy for patients with acute myeloid leukemia in first remission after conventional chemotherapy.	Dr Presgrave Danielle di Pietro (ICCC) Kyrie Rodgers (SCCC)	
	<u>AML22/D1</u> : The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.	Dr Presgrave Patricia Bly-ton	
Myelofibrosis	<u>CA011-023</u> : A phase 1b study of BMS-986158 monotherapy and in combination with either ruxolitinib or fedratinib in participants with DIPSS-intermediate or high risk myelofibrosis (CA011-023).	Dr Presgrave Lisa Kelly	
Chemotherapy Induced Nausea and Vomiting	<u>Cannabis CINV</u> : Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting.	Dr Aghmesheh Danielle di Pietro	
Lymphoma (Non-Hodgkin's and Hodgkin's)	<u>ALLG NHL30 - PETReA</u> : Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma.	Dr Presgrave Tia Summer-side	
	<u>MOR208C310</u> : A phase 3, multicenter, randomized, double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP vs R-CHOP in previously untreated, high intermediate and high risk patients with newly diagnosed diffuse large B-Cell lymphoma (DLBCL).	Dr Presgrave Patricia Bly-ton	
	<u>INCMOR208-301</u> : A phase 3, randomised double-blind, placebo controlled multicenter trial to evaluate the efficacy and safety of tafasitamab plus lenalidomide in addition to rituximab versus lenalidomide in addition to rituximab in patients with relapsed/refractory follicular lymphoma Grade 1 to 3A or R/R marginal zone lymphoma.	Dr Presgrave Lisa Kelly	